Literature DB >> 32995919

Comparison of the effect of continuous and standard intermittent bolus paracetamol infusion on patent ductus arteriosus.

Ufuk Cakir1, Cuneyt Tayman2, Nazmiye Bengu Karacaglar2, Esra Beser2, Burak Ceran2, Handan Unsal3.   

Abstract

The aim of this study was to evaluate the effect of paracetamol on patent ductus arteriosus (PDA) closure and clinical outcomes in preterm infants when used as standard intermittent bolus and continuous intravenous (IV) infusion. Preterm neonates with birth weight (BW) ≤ 1500 g and gestational age (GA) ≤ 30 weeks were included in this study. During the study period, IV paracetamol therapy was given to all infants with hemodynamically significant patent ductus arteriosus (hsPDA). The patients were divided into the standard IV intermittent bolus infusion group and the continuous IV infusion group. Standard IV intermittent bolus paracetamol therapy was administered in the form of 15-mg/kg doses as 1-h infusions every 6 h for 5 days, while continuous IV paracetamol infusion therapy was administered as a 60-mg/kg/day dose continuously for 5 days. During the study period, 247 patients were evaluated, of which a total of 137 patients with hsPDA were included. There were no significant differences between the intermittent bolus and continuous infusion groups in terms of mean GA or BW. The continuous paracetamol infusion group had significantly higher rates of PDA-related morbidities, multiple paracetamol courses, and PDA ligation procedure compared with the standard intermittent bolus group.
Conclusion: Our results were the first in the literature to compare IV paracetamol infusion regimens for PDA. Our results indicate that standard intermittent bolus infusion is still the most appropriate IV paracetamol regimen for the treatment of PDA.Trial registration: ClinicalTrials.gov Identifier: NCT04469413 What is Known: • Paracetamol has been proposed for the treatment of patent ductus arteriosus in preterm neonates. • There is no consensus on the duration and form of administration of paracetamol in hsPDA, and the information on this issue is insufficient. What is New: • Our study was the first in the literature to compare IV paracetamol infusion regimens for PDA. • Standard intravenous intermittent bolus paracetamol infusion was more effective in pharmacologic PDA closure compared with continuous intravenous paracetamol infusion and was associated with lower rates of PDA-related BPD, NEC, and need for ligation.

Entities:  

Keywords:  Continuous paracetamol infusion; Hemodynamically significant patent ductus arteriosus; Preterm; Standard intermittent paracetamol infusion; Very low birth weight

Mesh:

Substances:

Year:  2020        PMID: 32995919     DOI: 10.1007/s00431-020-03822-1

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  25 in total

Review 1.  Preterm patent ductus arteriosus: A continuing conundrum for the neonatologist?

Authors:  Nick Evans
Journal:  Semin Fetal Neonatal Med       Date:  2015-03-25       Impact factor: 3.926

2.  Comparative study of the efficacy and safety of paracetamol, ibuprofen, and indomethacin in closure of patent ductus arteriosus in preterm neonates.

Authors:  Abd El-Rahman El-Mashad; Heba El-Mahdy; Doaa El Amrousy; Marwa Elgendy
Journal:  Eur J Pediatr       Date:  2016-12-21       Impact factor: 3.183

3.  Gastrointestinal complications associated with ibuprofen therapy for patent ductus arteriosus.

Authors:  R Rao; K Bryowsky; J Mao; D Bunton; C McPherson; A Mathur
Journal:  J Perinatol       Date:  2011-01-20       Impact factor: 2.521

Review 4.  Safety of therapeutics used in management of patent ductus arteriosus in preterm infants.

Authors:  Mehmet Yekta Oncel; Omer Erdeve
Journal:  Curr Drug Saf       Date:  2015

5.  Safety, reliability, and validity of a physiologic definition of bronchopulmonary dysplasia.

Authors:  Michele C Walsh; Deanna Wilson-Costello; Arlene Zadell; Nancy Newman; Avroy Fanaroff
Journal:  J Perinatol       Date:  2003-09       Impact factor: 2.521

6.  Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging.

Authors:  M J Bell; J L Ternberg; R D Feigin; J P Keating; R Marshall; L Barton; T Brotherton
Journal:  Ann Surg       Date:  1978-01       Impact factor: 12.969

Review 7.  Continued uncertainty regarding treatment of patent ductus arteriosus in premature infants and the role of clinical trials.

Authors:  Edmund Juszczak; Samir Gupta
Journal:  Semin Fetal Neonatal Med       Date:  2018-03-07       Impact factor: 3.926

8.  A Mystery of Patent Ductus Arteriosus and Serum Osmolality in Preterm Infants.

Authors:  Ufuk Cakir; Cuneyt Tayman
Journal:  Am J Perinatol       Date:  2018-10-06       Impact factor: 1.862

9.  Limited effects of intravenous paracetamol on patent ductus arteriosus in very low birth weight infants with contraindications for ibuprofen or after ibuprofen failure.

Authors:  Daniëlla W E Roofthooft; Ingrid M van Beynum; Johan C A de Klerk; Monique van Dijk; John N van den Anker; Irwin K M Reiss; Dick Tibboel; Sinno H P Simons
Journal:  Eur J Pediatr       Date:  2015-04-30       Impact factor: 3.183

10.  Early PARacetamol (EPAR) trial: a study protocol for a randomised controlled trial of early paracetamol to promote closure of the ductus arteriosus in preterm infants.

Authors:  Tim Schindler; John Smyth; Srinivas Bolisetty; Joanna Michalowski; Kei Lui
Journal:  BMJ Open       Date:  2019-10-30       Impact factor: 2.692

View more
  1 in total

Review 1.  Different approaches for patent ductus arteriosus in premature infants using acetaminophen.

Authors:  Aimann Surak; Amish Jain; Abbas Hyderi
Journal:  World J Pediatr       Date:  2022-03-06       Impact factor: 2.764

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.